Behavioral Pharmacology


The In Vivo Pharmacology team within the Vanderbilt Center for Neuroscience Drug Discovery provides pharmacologic characterization of novel ligands in development in both established and novel preclinical models of various CNS disorders, including schizophrenia, Parkinson’s Disease, Fragile X Syndrome, Alzheimer’s Disease, PTSD. We utilize a range of translational approaches, including assessment of changes in behavior, neurochemistry and imaging endpoints such as PET and functional MRI, to explore the underlying mechanisms of novel ligands targeting different G protein-coupled receptors (GPCR) and transporters within the CNS and the implications of these effects on different disease states, most notably schizophrenia. We work in strong collaboration with all areas of the VCNDD, including medicinal chemistry, in vitro pharmacology and DMPK. In addition, we also work closely with the more basic science aspects of the Jones, Conn and Lindsley Laboratories, as the development of better tool compounds allows more in-depth investigation of the in vivo biology of our discovery targets.